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Hamilton, Ontario, Canada 
Abstract ~agonists have been widely used in the treatment of asthma for many years. Although concerns have been 
expressed over their safety, based largely upon epidemics of increased mortality in asthmatics associated with high doses 
of isoprenaline in the 1960s and fenoterol in the 1970s and 1980s, the specific/~2-agonists are vital drugs in asthma manage- 
ment.The short-acting/~2-agonists have an important prophylactic role in the prevention of exercise-induced broncho- 
constriction, and are essential in the emergency treatment of severe asthma. However, little if any benefit seems to be 
derived from regular use of short-acting/~2-agonists and regular or frequent use can increase the severity of the condi- 
tion. The development of/~2-agonists with long-acting properties, such as salmeterol and formoterol, has provided ad- 
vantages over short-acting/8-agonists, uch as prolonged bronchodilation, reduced day- and night-time symptoms and 
improved quality of sleep, and has reduced the requirement for short-acting /82-agonists as relief medication. Both drugs 
are well tolerated and, when added to inhaled corticosteroids, produce greater improvement in lung function than in- 
creased steroid dose alone. Because of its rapid onset of action, formoterol also has the potential to be used for as-needed 
bronchodilator therapy in asthma. 
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INTRODUCTION 
/~-agonists have a central role in the treatment of asthma. 
Their discovery represents a milestone in physiology as 
well as in clinical medicine. These agents are classified 
both by the receptors which they activate and by their 
onset and duration of action, particularly important fea- 
tures for asthma management. While the early/~-ago- 
nists lacked receptor specificity and produced many 
side effects, development of short- and long-acting/~2- 
agonists enabled the therapeutic benefit to be focussed 
where it was most needed. 
EARLY DEVELOPMENTS 
/~-agonists were used in the treatment of asthma long 
before their mechanism of action was understood. Ephe- 
drine, for example, an alkaloid originally derived from the 
plant Ephedra equisetina, has been known in Chinese 
medicine for at least 5000 years as a drug to treat disor- 
ders of the respiratory tract but it was only introduced 
into Western medicine in the 1920s. Adrenaline (epi- 
nephrine) was isolated in 1902 but, although effective in 
Correspondence should be addressed to: M.R. Sears, Firestone 
Institute for Respiratory Health, St Joseph's Hospital, 50 Charlton 
Avenue East, Hamilton, Ontario Canada L8N 4A6. Fax: (+905) 5216132; 
E-mail: searsm@mcmaster.ca 
relaxing airway smooth muscle in asthma, was asso- 
ciated with side effects because of its actions in other 
body systems. A more potent bronchodilating agent, iso- 
prenaline (isoproterenol), was developed in the 1940s, 
but this also produced unpleasant side effects such as 
palpitations, tachycardia and headache. In the 1940s, Ahl- 
quist showed that adrenaline and isoprenaline had differ- 
ent effects on smooth muscle: adrenaline was more 
potent than isoprenaline in muscle which responded by 
contraction but the opposite was true in muscle which 
responded by relaxation (I). This prompted the concept 
that tissues contain different types of adrenoceptor and 
that drugs act as agonists at different receptors. Two re- 
ceptors were initially classified (designated a-receptors 
and/~-receptors), and then subdivided as further proper- 
ties were identified. The/%receptors, for example, were 
subdivided into/~l, located in the heart and intestinal 
smooth muscle, and /~2, located in bronchial, vascular 
and uterine smooth muscle (2). Since the selectivity of 
drugs for different receptors would have an effect on 
their safety profiles, there was clearly a need to develop 
more selective drugs for the long-term treatment of 
asthma. 
Isoprenaline was found to be a non-selective/G-adre- 
noceptor agonist (i.e. it has activity at both ~l- and/~2- 
receptors) with a short duration of action (I.5-3 h). The 
effect on/~-receptors in the heart, leading to myocardial 
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stimulation, cardiac arrhythmia, depressed arterial 
blood gas tension and hypoxaemia, possibly exacerbated 
by a tendency for overuse due to its short duration of 
action, was considered by many to have led to the in- 
creased mortality amongst young asthmatics using the 
drug in the 1960s. This followed the introduction into 
some markets (U.K., New Zealand, Ireland, Australia 
and Norway) of a higher-dose formulation (five-times 
higher) of isoprenaline (3). Although the real cause of 
the 1960s increase in mortality was not ascertained, epi- 
demics of mortality subsequently declined when use of 
the higher dose came under greater control. However, 
the need for fi-agonists to be more selective was clear 
and attention focused on the fi2-receptors. 
SHORT-ACTING #z-AGONISTS 
Orciprenaline, a structural analogue of isoprenaline, be- 
came available in the early 1970s and combined reduced 
potency with longer duration of action. Orciprenaline 
was an effective bronchodilator when inhaled but did 
not discriminate between f ir  and fl2-receptors, again 
producing cardiac side effects. However, orciprenaline 
was quickly overshadowed by salbutamol, unsurpassed 
for almost 30 years as the most widely used short-acting 
fl2-agonist for the relief of asthma symptoms. Salbuta- 
mol has been shown to have high therapeutic efficacy 
and to be well tolerated in patients of all ages with asth- 
ma, improving airflow within minutes of inhalation and 
improving lung function for up to 6 h (4). For many pa- 
tients, salbutamol has become the first-line treatment 
for asthma symptoms and an effective prophylactic agent 
for exercise-induced bronchoconstriction (EIB) (4). Sal- 
butamol has also become the standard emergency treat- 
ment for asthma in many countries (5). 
Although designed for symptomatic treatment of asth- 
ma, salbutamol rapidly became established in routine 
management of the condition. One short trial of regular 
(four-times daily) treatment with salbutamol for I week 
showed reduced need for relief medication and an in- 
crease in evening peak expiratory flow rate compared 
with as-needed use (6).The use of regular treatment as a 
way of maintaining maximal airway dilatation seemed lo- 
gical, especially when combined with the apparent ab- 
sence of safety concerns. This led to the development of 
other short-acting fiz-agonists and the widespread accep- 
tance of this form of therapy during the late 1970s. Drugs 
such as fenoterol and terbutaline also became very widely 
used, but not to the same extent as salbutamol. 
Fenoterol is structurally related to orciprenaline but is 
more selective than the parent drug for fl2-receptors; it 
has a longer duration of action than isoprenaline and less 
effect on heart rate (7). Fenoterol was particularly pop- 
ular in the New Zealand market in the late 1970s but its 
introduction was subsequently noted to be associated 
with another increase in asthma mortality in 1977 and 
1978. At this time, the mortality rate amongst New 
Zealand's asthmatics under 70 years of age was three 
times that of the U.K. (8). Many factors were considered 
as potentially responsible, including poor assessment of 
the condition, underestimation of severity and inap- 
propriate treatment (especially over-reliance on bronch- 
odilators and underuse of systemic corticosteroids) (9). 
However, later case-control studies reviewing data from 
the New Zealand Asthma Mortality Study implicated fe- 
noterol administered by metered dose inhaler, particu- 
larly in patients with severe asthma (10-12). A further 
study in Canada confirmed the risk associated with feno- 
terol but suggested that other factors may also be in- 
volved (13). These included the dose taken (fenoterol 
was administered in a higher dose formulation than 
other drugs of the class, typically 200/,g/inhalation com- 
pared with salbutamol 100/*g/inhalation); the degree of 
illness associated with the patients themselves (more po- 
tent drugs were prescribed for particularly ill patients 
who would, by definition, already be at increased risk); 
potential effects of fi-agonists on organ systems other 
than the lungs (especially the heart); and the possible det- 
rimental effects of flz-agonists increasing airway hyper- 
responsiveness. However, these studies also alerted 
clinicians that patients may have become overreliant on 
one form of treatment, and patients may have felt that 
the fiz-agonist was stabilizing their asthma because 
symptoms were controlled.This may have resulted in pa- 
tients neglecting other medications, especially anti- 
inflammatories, to the extent that the disease eventually 
became life-threatening. Nonetheless, the withdrawal of 
fenoterol from the Drug Tariff in New Zealand in 1990 
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Figure I. Trends in asthma mortality and hospital admissions 
in 5- to 54-year-old New Zealanders, illustrating an abrupt de- 
crease in mortality rates following publication of the first case- 
control study in 1989 and withdrawal of fenoterol in 1990 (15). 
[Reproduced with permission from Can RespirJ.] 
$4 RESPIRATORY MEDICINE 
proved sufficient to bring about an abrupt fall in asthma 
morbidity and mortality during the following years 
(Fig. I)(14,15). 
At this time, long-term studies were also suggesting 
that excessive use of inhaled fi2-agonists in asthma might 
actually harm patients. In a year long, double-blind, pla- 
cebo-controlled, randomized study, regular treatment 
with fenoterol was compared with as-needed fi-agonist 
treatment (16,17). In this study, the regular intake of feno- 
terol (equivalent to 1600#g daily) compared with as 
needed (typically less than 300 #g daily) led to decreased 
values for forced expiratory volume in I second (FEVI), 
forced vital capacity and morning peak flow. Regular use 
was also associated with double the diurnal variation of 
peak flow rates, shorter time to first exacerbation, low- 
er concentration of methacholine producing a 20% fall in 
FEVj (PC20) and a greater number of hospitalizations (Ta- 
ble I). Regular use of salbutamol was also shown to offer 
no benefit, resulting in a worsening of EIB (although pro- 
phylactic use was still effective) (18), while a U.S. study 
involving 255 patients concluded that there was no ad- 
vantage when the drug was taken more often than 
strictly necessary (19). Combined with studies on other 
bronchodilators, this suggested that excessive use of in- 
haled short-acting fi2-agonists could increase asthma se- 
verity, increasing airway responsiveness both to specific 
allergen challenge and to non-specific bronchoconstric- 
tor agents (17,20-22). Thus, concerns were raised over 
excessive use of inhaled fi2-agonists, and there was much 
discussion over the clinical significance of the results 
(23-25). However, there was no suggestion that these 
drugs should no longer be used in the treatment of asth- 
ma. Short-acting fi2-agonists provide rapid onset of 
bronchodilation, protect against the early asthmatic re- 
sponse to allergens and have a vital role in the emergency 
treatment of severe asthma.The association between fi2- 
agonist use and increased morbidity and mortality from 
asthma was thought to relate to a cumulative effect over 
months or years, tending to increase airway responsive- 
ness and hence the severity of the condition (26). 
LONG-ACTING flrAGONISTS 
A major limitation of the fi-agonists in use during the 
1960s and 1970s was their short duration of action, typi- 
cally 4 -6  h. This was clearly inadequate to protect from 
bronchospasm through the night or for convenient main- 
tenance therapy. The challenge was to develop a drug 
which would be effective for more than 12h. In the 
1980s, the long-acting fi2-agonist salmeterol was devel- 
oped (27) and formoterol, originally developed as a con- 
ventional fi2-agonist for oral use, was found to be long- 
acting when taken by inhalation. Salmeterol and formo- 
terol share similar properties and provide prolonged 
bronchodilation, reduction in day- and night-time symp- 
toms, improved quality of sleep and reduced require- 
ment for short-acting fi2-agonists (22). However, while 
salmeterol is a partial agonist at the fi2-adrenoceptor, 
achieving maximum effect after about 60 min (28), for- 
moterol is almost a full agonist, achieving a more rapid 
onset of action with substantial effect at 5 min similar 
to salbutamol (29). Both drugs have durations of effect 
exceeding 12 h and both are recommended for regular 
use at 12-h intervals. Although in higher doses both may 
produce predictable sympathomimetic adverse events, 
including tremor and slight tachycardia, both are very 
well-tolerated drugs. 
These fi2-agonists with long-acting properties were 
monitored closely in light of the concern over short-act- 
ing agents. Salmeterol and salbutamol were compared in 
a 16-week clinical trial involving more than 25 000 pa- 
tients with asthma, considered to require treatment 
with bronchodilators (30). This was the largest rando- 
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mized, double-blind clinical trial ever conducted in the 
U.K. and suggested that overall control of asthma was 
better in patients allocated to salmeterol, although mor- 
tality was not decreased. A 6-month study of formoter- 
ol in subjects using inhaled corticosteroids showed 
improved lung function with no evidence for worsening 
asthma (31). Addition of a long-acting ~2-agonist to ther- 
apy with inhaled steroids was shown to produce a great- 
er improvement in symptoms and lung function than 
increasing the steroid dose alone (32,33), and a study ex- 
amining the combined effects of formoterol with inhaled 
budesonide (the FACET [Formoterol And Corticoster- 
oids EstablishingTherapy] study) demonstrated a signifi- 
cant reduction in asthma exacerbations for the 
combined therapy (34). 
Concerns have been expressed over the use of/~2-ago- 
nists with long duration of action, however, and these 
need to be addressed.The potential for masking of symp- 
toms of increasing airway inflammation, delaying aware- 
ness of worsening asthma, remains a theoretical concern 
and any reduction of inhaled corticosteroid dose in com- 
bination therapy should clearly be done with care (35). 
Tolerance to the bronchoprotective actions of these 
agents against non-specific challenge (36), exercise chal- 
lenge (37,38) and allergen challenge (39) has been demon- 
strated. Although these effects indicate potential 
limitations for such long-acting therapies, the clinical sig- 
nificance of these observations is questionable; the de- 
velopment of tolerance seems confined to the early 
weeks of treatment (40) and some bronchoprotection 
is maintained during long-term treatment (41). 
~2-agonists with long-acting properties are now well 
established as therapeutic options in the management of 
asthma.They are included in current guidelines as recom- 
mended add-on therapy for asthma not controlled with 
a modest dose of inhaled corticosteroid and occasional 
use of short-acting bronchodilator (42-44). 
The future role for one of these agents, formoterol, 
for as-needed therapy in asthma is now being investi- 
gated. Formoterol has been shown to have both a fast 
onset of effect and long duration of action (45-47) mak- 
ing it potentially suitable for this role in addition to its 
established role as a maintenance therapy in asthma. 
The question is whether formoterol will be more 
effective, and equally safe, as the currently recom- 
mended short-acting /~2-agonists for as-needed symp- 
tom relief. 
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